Isomorphic Labs
An AI drug discovery company under Alphabet that uses machine learning to accelerate drug design and the research and development process.
Core Facts
Timeline (last 90 days)
IsoDDE can discover cryptic pockets on proteins (hidden binding sites that open only when a drug molecule is present) and simulate protein conformational changes during drug binding.
In February 2026, Isomorphic Labs released the Drug Design Engine (IsoDDE), and a technical report states that its performance on protein-ligand structure prediction is twice that of AlphaFold 3, its binding affinity prediction accuracy is higher than physics-based methods, and its time and cost are far lower than the latter.
In May 2026, Isomorphic Labs completed a $2.1 billion financing, one of the largest private financings on record in the biotechnology field.
Argon's early enterprise testers include Deloitte, LexisNexis, Ambience Healthcare, and Isomorphic Labs.
Early enterprise testers include Deloitte, LexisNexis, Ambience Healthcare, and Isomorphic Labs.
The researcher estimated that generating reports for 10 different patents would require nearly a month of continuous work in the traditional way, whereas Gemini 4 completed the same task in a single afternoon.
The models developed by Isomorphic Labs are highly focused on specific tasks, such as predicting protein three-dimensional structures from amino acid sequences, with advantages of high accuracy and reproducibility.
There is a division of labor between specialized models and general-purpose models in drug discovery: specialized models target specific tasks (such as structure prediction), while general-purpose large models (such as Gemini 4), with their common-sense reasoning and cross-domain connection capabilities, can serve as an orchestration layer integrating the outputs of specialized models with unstructured information such as literature and patents.
The researcher believes that the value of general-purpose models like Gemini 4 lies in coordinating and orchestrating the work surrounding drug discovery, helping save time and resources, guiding researchers onto the right path, and ultimately accelerating better drugs reaching patients.
A staff member at Isomorphic Labs engaged in drug discovery research obtained early access to Gemini 4 and shared the experience in a YouTube video.
4 more timeline events
All Facts (12)
Isomorphic Labs was founded in 2021 and is an independently operated AI pharmaceutical company under Alphabet.
75%UnverifiedIsomorphic Labs was founded by DeepMind co-founder Demis Hassabis.
90%UnverifiedIsomorphic Labs采用从物理第一性原理出发的结构引导药物设计方法论，区别于纯统计学习方法
75%UnverifiedIsoDDE can discover cryptic pockets on proteins (hidden binding sites that open only when a drug molecule is present) and simulate protein conformational changes during drug binding.
50%UnverifiedArgon's early enterprise testers include Deloitte, LexisNexis, Ambience Healthcare, and Isomorphic Labs.
50%UnverifiedThe models developed by Isomorphic Labs are highly focused on specific tasks, such as predicting protein three-dimensional structures from amino acid sequences, with advantages of high accuracy and reproducibility.
50%UnverifiedThe researcher believes that the value of general-purpose models like Gemini 4 lies in coordinating and orchestrating the work surrounding drug discovery, helping save time and resources, guiding researchers onto the right path, and ultimately accelerating better drugs reaching patients.
50%UnverifiedThere is a division of labor between specialized models and general-purpose models in drug discovery: specialized models target specific tasks (such as structure prediction), while general-purpose large models (such as Gemini 4), with their common-sense reasoning and cross-domain connection capabilities, can serve as an orchestration layer integrating the outputs of specialized models with unstructured information such as literature and patents.
50%UnverifiedThe researcher stated that manually completing the same protein target paper summarization work would take at least one to two days.
50%UnverifiedThe Isomorphic Labs team used Argon for drug discovery and design research, compressing processes that usually take weeks into hours.
50%UnverifiedIn February 2026, Isomorphic Labs released the Drug Design Engine (IsoDDE), and a technical report states that its performance on protein-ligand structure prediction is twice that of AlphaFold 3, its binding affinity prediction accuracy is higher than physics-based methods, and its time and cost are far lower than the latter.
50%UnverifiedIn May 2026, Isomorphic Labs completed a $2.1 billion financing, one of the largest private financings on record in the biotechnology field.
50%